No Data
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Replimune Begins RP2 Clinical Trials With First Patients Enrolled In Metastatic Uveal Melanoma And Hepatocellular Carcinoma
Express News | Replimune Group Inc - Primary Endpoints of Rp2-202 Study Are Overall Survival and Progression Free Survival
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Replimune Management to Meet With Jefferies